

# **Human IL-22 Rα1 Biotinylated Antibody**

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: BAF2770

DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human IL-22 Rα1 in Western blots. In Western blots, less than 1% cross-reactivity with recombinant human (rh) IL-20 Rα, rhIL-20 R and rhIL-22BP is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human IL-22 Rα1 Pro18-Thr228 Accession # Q8N6P7		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.		

## **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Treads Note: Optimal alliations of out in the following of out in about only for out in approach.			
	Recommended Concentration	Sample	
Western Blot	0.1 μg/mL	Recombinant Human IL-22 Rα1 (Catalog # 2770-LR)	

# PREPARATION AND STORAGE Reconstitution Reconstitute at 0.2 mg/mL in sterile PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

### BACKGROUNE

IL-22 receptor, also known as IL-22 R $\alpha$ 1 and CRF2-9, is an approximately 65 kDa transmembrane glycoprotein in the type II cytokine receptor family (CRF). IL-22 R $\alpha$ 1 contains a 211 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, and a 323 aa cytoplasmic domain. IL-22 R $\alpha$ 1 associates with either IL-10 R $\beta$  or IL-20 R $\beta$  to form receptor complexes with distinct ligand selectivities. IL-10 R $\beta$  is a shared subunit of the IL-10, -22, -26, -28, and -29 receptors, while IL-20 R $\beta$  is a shared subunit of the IL-19, -20, -22R and -24 receptors (1). IL-22 R $\alpha$ 1/IL-10 R $\beta$  is an IL-22 responsive receptor (2, 3), and IL-22 R $\alpha$ 1/IL-20 R $\beta$  is an IL-20 or IL-24 responsive receptor (4, 5). IL-22 R $\alpha$ 1 contains cytoplasmic motifs for interactions with signal transduction molecules, but formation of ternary complexes with IL-10 R $\beta$  or IL-20 R $\beta$  and the respective ligands is required for signal transduction (2, 6). IL-22BP functions as a competitive antagonist by binding IL-22 and preventing its association with IL-22 R $\alpha$ 1 (7, 9). Even though it is a receptor for interleukins, IL-22 R $\alpha$ 1 is not expressed on hematopoietic cells (6, 10, 11). Instead, IL-22 R $\alpha$ 1 expression is restricted to epithelial and stromal cells (6, 10-13). IL-22 R $\alpha$ 1 signaling promotes innate immune responses and wound healing at sites of infection and inflammation. This includes upregulation of antimicrobial, acute phase, proinflammatory, and extracellular matrix proteins as well as proteases (3, 11, 13, 14). IL-22 R $\alpha$ 1 signaling also promotes downregulation of proteins involved in keratinocyte differentiation (3, 14). Within the ECD, human IL-22 R $\alpha$ 1 shares 78%, 76%, and 83% as sequence identity with mouse, rat, and canine IL-22 R, respectively. It shares 22%-25% as sequence identity with the ECDs of other class II receptors IL-10 R, IL-20 R, and IL-28 R.

## References:

- 1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
- Xie, M.-H. et al. (2000) J. Biol. Chem. 275:31335.
- 3. Boniface, K. *et al.* (2005) J. Immunol. **174**:3695.
- 4. Dumoutier, L. et al. (2001) J. Immunol. 167:3545
- 5. Wang, M. et al. (2002) J. Biol. Chem. 277:7341.
- 6. Kotenko, S.V. et al. (2001) J. Biol. Chem. 276:2725
- 7. Li, J. et al. (2004) Int. Immunopharmacol. **4**:693.
- 8. Logsdon, N.J. et al. (2002) J. Interferon Cytokine Res. 22:1099.
- 9. Kotenko, S.V. et al. (2001) J. Immunol. 166:7096.
- 10. Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:577.
- 11. Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:679.
- 12. Aggarwal, S. et al. (2001) J. Interferon Cytokine Res. 21:1047.
- 13. Wolk, K. et al. (2004) Immunity 21:241.
- 14. Wolk, K. et al. (2006) Eur. J. Immunol. 36:1309.

